NERVIANO, IT and BOSTON, Mass, December 1, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced today the appointment of Serena Alvino as its Chief Legal, Biotech & Transaction, effective immediately.
In this role, Serena will be responsible for providing strategic legal counsel to the executive team and ensuring compliance with applicable laws and regulations. In particular, she will spearhead the legal aspects of strategic transactions, including but not limited to licensing agreements, collaborations, overseeing quality, Intellectual protection filling, litigation, legal risk protection and other key initiatives. Serena will also act as legal advisor of NMS Group Spa Board of directors.
With a proven track record in all legal areas with a special focus on biotech and pharma, e.g., intellectual property, regulatory compliance, and corporate governance, and successfully orchestrated legal strategies that contributed to the success and growth of the organizations where she served, Serena demonstrated exceptional legal acumen and leadership.
Serena joins us from Dompé, renowned for its contributions to the biopharmaceutical sector, where she served as Chief Legal Officer and DPO, overseeing legal matters across the U.S., China, and Albania. She brings a wealth of experience from key roles at Reckitt Benckiser Healthcare Italia (Italia) SpA and Recordati Industria Chimica e Farmaceutica SpA in Milan, where she played pivotal roles in compliance, commercial contracts, and corporate legal matters.
Commenting on the appointment, Hugues Dolgos, Pharm.D., Chief Executive Officer., stated, “We are delighted to welcome Serena to NMS. Her proven expertise in structuring and negotiating transactions in the biotechnology and pharma sector aligns seamlessly with our vision for advancing our innovative pipeline. Serena’s leadership will be instrumental as we explore strategic opportunities and collaborations to propel our company forward while assuring us effective regulatory compliance.”
Serena expressed enthusiasm about joining NMS, stating, “I am thrilled to be part of NMS’s dynamic team and to lead the legal efforts in shaping strategic transactions that will drive the company’s success. I look forward to contributing to the continued growth and impact of NMS in the biotech industry.”
As NMS continues to position itself as a leader in discovering and developing innovative therapies for the treatment of cancer, Serena’s appointment underscores the company’s commitment to assembling a seasoned team capable of navigating the intricate legal landscape inherent in biotech transactions.
Link PR: 20231201 NMS appoints Serena Alvino as Chief Legal Biotech Transaction – Final
from NMSGroup
